Alvotech Holdings S.A
ISIN: LU2458332611 | Ticker: ALVO | LEI: 222100DCZBOWV5DZ8372
Country: Luxembourg
We specialize in making biosimilars – to improve lives by expanding access to affordable biologic medicines. We are purpose-driven and passionate about what we do.
We have a deep appreciation for the positive impact biologic medicines have had on health care. From insulin to vaccines to monoclonal antibody cancer therapies, biologic medicines are revolutionizing the way we treat diseases and improve patient lives.
It is our aim to broaden the availability of these important biologic medicines to patients around the world by developing and manufacturing high-quality, cost-competitive biosimilars.
Our commitment to the promise of biosimilars is foundational to our approach, our culture and the strong sense of purpose that inspires us to work smarter and faster towards this mission.
We are driven by passion - if there is a proven biologic medicine, we believe it should be accessible to all patients in need.
2018
Served areaWorldwide
Headquarters9 rue de Bitbourg, 1273 Luxembourg – Luxembourg
| Line item in (usd) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 597,977,000.00 | 828,443,000.00 |
| Noncurrent Assets | N/A | 478,161,000.00 | 597,707,000.00 |
| Property Plant And Equipment | N/A | 78,530,000.00 | 220,594,000.00 |
| Goodwill | N/A | 12,367,000.00 | 11,643,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 21,509,000.00 | 25,652,000.00 |
| Investments In Joint Ventures Accounted For Using Equity Method | N/A | 55,307,000.00 | 48,568,000.00 |
| Deferred Tax Assets | N/A | 170,418,000.00 | 209,496,000.00 |
| Noncurrent Restricted Cash And Cash Equivalents | N/A | 10,087,000.00 | 25,187,000.00 |
| Other Noncurrent Assets | N/A | 1,663,000.00 | 5,780,000.00 |
| Current Assets | N/A | 119,816,000.00 | 230,736,000.00 |
| Inventories | N/A | 39,058,000.00 | 71,470,000.00 |
| Current Trade Receivables | N/A | 29,396,000.00 | 32,972,000.00 |
| Trade And Other Current Receivables Due From Related Parties | N/A | 1,111,000.00 | 1,548,000.00 |
| Cash and cash equivalents | 31,689,000.00 | 17,556,000.00 | 66,427,000.00 |
| Other Current Assets | N/A | 14,736,000.00 | 32,949,000.00 |
| Equity And Liabilities | N/A | 597,977,000.00 | 828,443,000.00 |
| Equity | -867,243,000.00 | -135,612,000.00 | -564,416,000.00 |
| Issued Capital | N/A | 135,000.00 | 2,126,000.00 |
| Retained Earnings | N/A | -1,140,534,000.00 | -1,654,114,000.00 |
| Share Premium | N/A | 1,000,118,000.00 | 1,058,432,000.00 |
| Liabilities | N/A | 733,589,000.00 | 1,392,859,000.00 |
| Noncurrent Liabilities | N/A | 621,753,000.00 | 1,225,565,000.00 |
| Noncurrent Payables To Related Parties | N/A | 7,440,000.00 | 7,440,000.00 |
| Noncurrent Contract Liabilities | N/A | 44,844,000.00 | 57,017,000.00 |
| Deferred Tax Liabilities | N/A | 150,000.00 | 309,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 0.00 | 380,232,000.00 |
| Longterm Borrowings | N/A | 398,140,000.00 | 744,654,000.00 |
| Current Liabilities | N/A | 111,836,000.00 | 167,294,000.00 |
| Trade And Other Current Payables To Related Parties | N/A | 638,000.00 | 1,131,000.00 |
| Current Contract Liabilities | N/A | 29,692,000.00 | 36,915,000.00 |
| Current Tax Liabilities Current | N/A | 841,000.00 | 934,000.00 |
| Other Current Liabilities | N/A | 42,012,000.00 | 54,047,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 2,771,000.00 | 19,916,000.00 |
| Line item in (usd) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue From Sale Of Goods | 0.00 | 24,836,000.00 |
| Revenue From Contracts With Customers | 36,772,000.00 | 58,193,000.00 |
| Other Income | 2,912,000.00 | 1,988,000.00 |
| Profit Loss From Operating Activities | -235,456,000.00 | -346,442,000.00 |
| Finance Income | 51,568,000.00 | 2,549,000.00 |
| Finance Costs | 117,361,000.00 | 188,419,000.00 |
| Profit Loss Before Tax | -149,198,000.00 | -551,647,000.00 |
| Income Tax Expense Continuing Operations | -47,694,000.00 | -38,067,000.00 |
| Profit (loss) | -101,504,000.00 | -513,580,000.00 |
| Line item in (usd) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | N/A | -101,504,000.00 | -513,580,000.00 |
| Adjustments For Income Tax Expense | N/A | -47,694,000.00 | -38,067,000.00 |
| Adjustments For Finance Costs | N/A | 117,361,000.00 | 188,419,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -29,412,000.00 | -32,412,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 18,196,000.00 | 20,409,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | -2,681,000.00 | -10,566,000.00 |
| Adjustments For Sharebased Payments | N/A | 0.00 | 10,317,000.00 |
| Cash Flows From Used In Operations | N/A | -200,027,000.00 | -276,751,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 28,004,000.00 | 35,372,000.00 |
| Interest Received Classified As Operating Activities | N/A | 16,000.00 | 568,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -228,170,000.00 | -312,389,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 379,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 20,462,000.00 | 37,880,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 20,171,000.00 | 11,122,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -40,633,000.00 | -63,537,000.00 |
| Proceeds From Issuing Shares | N/A | 185,856,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 113,821,000.00 | 193,678,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 37,496,000.00 | 34,714,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 7,350,000.00 | 11,147,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 254,831,000.00 | 424,910,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -13,972,000.00 | 48,984,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -161,000.00 | -113,000.00 |
| Cash and cash equivalents | 31,689,000.00 | 17,556,000.00 | 66,427,000.00 |
Please note that some sums might not add up.
LU2458332611
LEI222100DCZBOWV5DZ8372
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryOMX Iceland All-Share Index
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.